Pharma’s transition continues apace, as the real, game-changing innovation it creates in areas such as cancer and hepatitis sees the question of how to reward these advances become evermore pressing.
Innovation is, after all, only meaningful if patients can access it. And that can only happen if health systems and industry stakeholders can come up with new ways of working together.
From outcomes-based reimbursement to managed entry agreements, the last few years have seen a range of approaches put in place, but there’s still more to be done. And that’s one of the main themes of this month’s issue, as we look at affordability and value.
Just as Sovaldi kick-started a new dialogue about affordability, the emerging gene therapies are taking that conversation to new heights. Beyond even greater partnership, we’re going to see a wider range of more radical strategies come under consideration to manage these high-cost, high-innovation products.
Continuing from this, we also hear from Novartis about its work in value-based healthcare and how the company is working to change the system.
Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
PME is also available to download as an app for iPhone and iPad
